Biotechnology major Biocon today reported a 47 per cent rise in its consolidated net profit to Rs 120 crore for the quarter ended June 2018 on account of robust performance across segments.
The company had posted a net profit of Rs 81 crore for the corresponding period of the previous fiscal, Biocon said in a filing to BSE.
Consolidated total revenue of the company stood at Rs 1,193 crore for the quarter under consideration. It was Rs 988 crore for the same period a year ago.
"We started the year with a robust Q1FY19 recording an overall revenue growth of 21 per cent at Rs 1,193 crore and a 47 per cent increase in net profit at Rs 120 crore, driven by a strong performance across our business segments," Biocon Chairperson and MD Kiran Mazumdar-Shaw said.
This performance was led by a 36 per cent growth in biologics business and a 39 per cent increase in research services revenues, she added.
"The approval and launch of our biosimilar Pegfilgrastim, Fulphila, in the US is a significant milestone for Biocon and sets the tone for the future success of our biosimilars business," Mazumdar-Shaw said.
Shares of Biocon Ltd today closed at Rs 559.10 per scrip on BSE, up 0.96 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)